Xiangjin Xu

Dr. Xiangjin Xu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
WGWen Guo
Wen Guo
WTWenjun Tian
Wenjun Tian
LLLu Lin
Lu Lin
XXXiangjin Xu
Xiangjin Xu

1 March 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
PCPin Chen
Pin Chen
XSXiaozhi Shi
Xiaozhi Shi
XXXiangjin Xu
Xiangjin Xu
YLYiyang Lin
Yiyang Lin
ZSZhulin Shao
Zhulin Shao
LHLihong Huang
Lihong Huang

14 August 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
WWWei Wang
Wei Wang
RWRong Dan Wu
Rong Dan Wu
.W.Wei Wang
.Wei Wang
XXXiangjin Xu
Xiangjin Xu
XSXiao Zhi Shi
Xiao Zhi Shi
WGWen Guo
Wen Guo

10 June 2021 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
SHSiyao He
Siyao He
XQXin Qian
Xin Qian
YCYanyan Chen
Yanyan Chen
XSXiaoxia Shen
Xiaoxia Shen
BZBo Zhang
Bo Zhang
GLGuangwei Li
Guangwei Li
Background. To assess the association of metformin monotherapy with the risk of all-cause deaths and cardiovascular deaths and events in type 2 diabetes patients in real clinical practice. Methods. This retrospective, observational study comprised patients with type 2 diabetes initially treated with metformin or nonmetformin monotherapy over 2011-2016. Data were extracted from the National Healthcare Big Data database in Fuzhou, China. Propensity score matching (PSM) was performed, matching each patient on metformin to one on nonmetformin in terms of a set of covariates. The primary endpoint was all-cause death, and secondary endpoints were cardiovascular death, heart failure, and heart failure hospitalization. Covariate-adjusted associations of metformin use with all the endpoints were assessed by Cox proportional hazards models. Results. Among 24,099 patients, 5491 were initially treated with metformin and 18,608 with nonmetformin. PSM yielded 5482 patients in each cohort. During a median follow-up of 2.02 years, we observed 110 and 211 deaths in the metformin and nonmetformin groups, respectively. Metformin was significantly associated with reduced risk of all-cause death (adjusted hazard ratio (aHR) 0.52, 95 confidence interval (CI) 0.39-0.69), cardiovascular death (aHR 0.63, 95 CI 0.43-0.91), and heart failure (aHR 0.61, 95 CI 0.52-0.73), whereas the reduced risk in heart failure hospitalization was not statistically significant (aHR 0.70, 95 CI 0.47-1.02). Conclusions. In this analysis of electronic health record data from a large database in China, metformin as first-line monotherapy greatly reduced the risk of all-cause death, cardiovascular death, and heart failure in diabetes patients as compared with nonmetformin medications.

1 June 2012
Verified
Journal Article
Closed access
PCPin Chen
Pin Chen
JCJing-Bo Chen
Jing-Bo Chen
WCWen-Yu Chen
Wen-Yu Chen
QZQuan-Lin Zheng
Quan-Lin Zheng
YWYan-Qiao Wang
Yan-Qiao Wang
XXXiangjin Xu
Xiangjin Xu

30 October 2024 in Archives of Medical Science
Verified
Journal Article
Open access
SHShulin Huang
Shulin Huang
KXKun Xie
Kun Xie
XLXiaohong Li
Xiaohong Li
XXXiangjin Xu
Xiangjin Xu
PCPin Chen
Pin Chen
Introduction: Studies have suggested a potential association between patients who have both psoriasis and diabetes and liver damage. However, the exact nature of this link has not yet been fully established. The objective of the current study was to examine the potential exacerbation of liver damage due to the coexistence of psoriasis and type 2 diabetes mellitus (T2DM) and to explore the impact of interferon gene stimulating factor (STING) on related damage.Material and methods: Four patient groups were recruited: normal individuals, individuals with diabetes, those with psoriasis, and those with both diabetes and psoriasis. Relevant indicators were collected to facilitate the investigation. Furthermore, a mouse model of psoriasis combined with T2DM was established. The expression levels of STING and inflammatory factors downstream of the pathway were detected in both the skin and liver tissues of the model mice.Results: Based on our findings, patients with both psoriasis and T2DM exhibit abnormal liver function and increased STING expression in the skin (p < 0.05). In the in vivo experiments, liver tissues from model mice exhibited significantly elevated expression of STING and its downstream inflammatory factors, including NF-κB p65, interferon-β, interleukin (IL)-17A, and IL-23 (p < 0.05). The STING inhibitor-treated group displayed reduced skin damage and improved liver histopathology (p < 0.05).Conclusions: The findings of the current study indicate that the STING inflammatory pathway is upregulated in the liver tissues of individuals with psoriasis and T2DM.